Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia

People diagnosed with hairy cell leukemia (HCL) may have an effective new treatment option, a type of drug called an immunotoxin. Read more about how this treatment, moxetumomab pasudotox, fared in a phase 3 clinical trial in patients with advanced HCL.

Cancer Currents: An NCI Cancer Research Blog